Table of Contents

August 01, 2004; Volume 71, Issue 8
  • From the Editor

  • Commentary

  • Interpreting Key Trials

      • Lessons from the PROVE-IT Trial

        Kiran K. Khush, MD and David Waters, MD
        • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 609-616;
        • Patients with acute coronary syndromes should receive aggressive lipid-lowering therapy with a statin in high doses. Goal low-density lipoprotein levels may need to be lower.

  • Cancer Diagnosis and Management

      • Cancer pain: How to measure the fifth vital sign

        Mellar P. Davis, MD and Declan Walsh, MSc
        • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 625-632;
        • To control pain effectively in cancer patients, we must assess it regularly and consistently.

  • Review

  • Im Board Review

      • A 76-year-old woman with erratic anticoagulation

        Emil P. Lesho, DO, Louise Saullo, CRTT and Szilvia Udvari-Nagy, MD
        • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 651-656;
        • A patient previously controlled on warfarin now has bleeding and an INR of 7. What has changed?

  • Review

      • Nonalcoholic fatty liver disease and the epidemic of obesity

        Rochelle Collantes, MD, MPH, Janus P. Ong, MD and Zobair M. Younossi, MD, MPH
        • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 657-664;
        • Nonalcoholic fatty liver disease, unknown only 2 decades ago, is now ubiquitous, especially among the obese.

  • Interpreting Key Trials

      • Angiotensin-receptor blockers in heart failure

        Shyam Bhakta, MD and Mark E. Dunlap, MD
        • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 665-673;
        • The ARB candesartan was not only a good alternative to an ACE inhibitor, it was beneficial when added to a regimen that already included an ACE inhibitor and a beta-blocker.

  • Editorial

      • And an ARB makes nine: Polypharmacy in patients with heart failure

        Josef Stehlik, MD, MPH and David O. Taylor, MD
        • Cleveland Clinic Journal of Medicine August 2004, 71 (8) 674-677;
        • Based on strong evidence, a patient with advanced ischemic cardiomyopathy should be taking nine medications. But it is difficult not to worry about polypharmacy.